title: All-trans retinoic acid potentiates the inhibitory effects of interferon alpha on chronic myeloid leukemia progenitors in vitro.
abstract: All-trans retinoic acid (ATRA) has recently been shown to synergize with the inhibitory effect of interferon alpha (IFN alpha) on the growth of malignant cells isolated from solid tumors. We investigated whether ATRA could potentiate the inhibitory effects of IFN alpha on the proliferation of leukemic progenitors in chronic myeloid leukemia (CML). CD34+ cells from chronic phase, newly diagnosed patients, were incubated in short-term liquid culture with ATRA, IFN alpha or a combination of both molecules and then plated on semi-solid cultures for colony-forming cell assay. IFN alpha was found to inhibit preferentially the generation of late progenitors. ATRA at a concentration of 10(-8) M was found strongly to inhibit CFU-M colonies. Addition of ATRA to IFN alpha dramatically potentiated the inhibitory effects of INF alpha on CFU-GM growth. In the presence of both molecules the inhibition of day 14 CFU-GM from CD34+ cells was lowered to 27 +/- 4% of control. CFU-M colonies were completely inhibited. RT-PCR analysis of the colonies resulting from the action of the combination IFN alpha plus ATRA showed the presence of an increased number of BCR-ABL-negative colonies relatively to what was observed with IFN alpha alone. FISH analysis showed a higher percentage of Ph-negative cells in the ATRA plus IFN alpha-treated samples, confirming PCR experiments. These results indicate that, in vitro, the combination of IFN alpha and ATRA effectively inhibits CFU-GM colony formation in CML and suggest that it has a potential interest for the treatment of CML.
authors.affiliation: Laboratoire de Greffe de Moelle, UMR CNRS 5540, and FR60, Université de Bordeaux 2, France.
authors.forename: F X
authors.initials: FX
authors.lastname: Mahon
authors.forename: H
authors.initials: H
authors.lastname: Chahine
authors.forename: C
authors.initials: C
authors.lastname: Barbot
authors.forename: V
authors.initials: V
authors.lastname: Pigeonnier
authors.forename: B
authors.initials: B
authors.lastname: Jazwiec
authors.forename: J
authors.initials: J
authors.lastname: Reiffers
authors.forename: J
authors.initials: J
authors.lastname: Ripoche
mesh_terms: D015703:Antigens, CD / Q000097:blood; D018952:Antigens, CD34 / Q000097:blood; D002455:Cell Division / Q000187:drug effects; D003114:Colony-Forming Units Assay; D004357:Drug Synergism; D016044:Fusion Proteins, bcr-abl / Q000096:biosynthesis; D006412:Hematopoietic Stem Cells / Q000187:drug effects / Q000473:pathology*; D006801:Humans; D007370:Interferon Type I / Q000494:pharmacology*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood* / Q000473:pathology; D012333:RNA, Messenger / Q000096:biosynthesis; D011994:Recombinant Proteins; D014158:Transcription, Genetic; D014212:Tretinoin / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
chemical_list: D015703:Antigens, CD; D018952:Antigens, CD34; D007370:Interferon Type I; D012333:RNA, Messenger; D011994:Recombinant Proteins; D014212:Tretinoin; D016044:Fusion Proteins, bcr-abl